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Background: Fixed-dose combinations of candesartan 32 mg and hydrochlorothiazide 
(HCTZ) have been shown to be effective in clinical trials. Upon market entry we conducted a 
noninterventional study to document the safety and effectiveness of this fixed-dose combination 
in an unselected population in primary care and to compare blood pressure (BP) values obtained 
during office measurement (OBPM) with ambulatory blood pressure measurement (ABPM).
Methods: CHILI CU Soon was a prospective, noninterventional, noncontrolled, open-label, 
multicenter study with a follow-up of at least 10 weeks. High-risk patients aged $18 years 
with previously uncontrolled hypertension were started on candesartan 32 mg in a fixed-dose 
combination with either 12.5 mg or 25 mg HCTZ. OBPM and ABPM reduction and adverse 
events were documented.
Results: A total of 4131 patients (52.8% male) with a mean age of 63.0 ± 11.0 years were included. 
BP was 162.1 ± 14.8/94.7 ± 9.2 mmHg during office visits at baseline. After 10 weeks of cande-
sartan 32 mg/12.5 mg or 25 mg HCTZ, mean BP had lowered to 131.7 ± 10.5/80.0 ± 6.6 mmHg 
(P , 0.0001 for both comparisons). BP reduction was comparable irrespective of prior or 
concomitant medication. In patients for whom physicians regarded an ABPM to be necessary 
(because of suspected noncontrol over 24 hours), ABP at baseline was 158.2/93.7 mmHg during 
the day and 141.8/85.2 mmHg during the night. At the last visit, BP had significantly reduced 
to 133.6/80.0 mmHg and 121.0/72.3 mmHg, respectively, resulting in 20.8% being normoten-
sive over 24 hours (,130/80 mmHg). The correlation between OBPM and ABPM was good 
(r = 0.589 for systolic BP and r = 0.389 for diastolic BP during the day). Of those who were 
normotensive upon OBPM, 35.1% had high ABPM during the day, 49.3% were nondippers, and 
3.4% were inverted dippers. Forty-nine adverse events (1.19%) were reported, of which seven 
(0.17%) were regarded as serious.
Conclusion: Candesartan 32 mg in a fixed-dose combination with either 12.5 mg or 25 mg 
HCTZ is safe and effective for further BP lowering irrespective of prior antihypertensive drug 
class not being able to control BP.
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Background
Fixed-dose combinations of candesartan 32 mg and hydrochlorothiazide (HCTZ) have 
been shown to be effective in clinical trials.1,2 Mean reductions in systolic blood pressure 
(SBP) and diastolic blood pressure (DBP) were significantly greater with candesartan 
32 mg/HCTZ 25 mg (21/14 mmHg) than with candesartan 32 mg (13/9 mmHg) or 
HCTZ 25 mg alone (12/8 mmHg).2 The addition of 12.5 mg HCTZ or 25 mg HCTZ Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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to 32 mg candesartan resulted in a further BP reduction 
by 13.0/8.8 mmHg in the HCTZ 12.5 mg group and by 
15.5/10.0 mmHg in the HCTZ 25 mg group in a study by 
Bönner.3 At the same time, adverse events (AEs) were scarce, 
with about 1% serious AEs when candesartan combination 
therapy including HCTZ was considered.2,3
Upon market entry we aimed to conduct a non inter-
ventional study to document the safety and effectiveness 
of this fixed-dose combination in an unselected population 
in primary care. These non interventional studies comple-
ment the findings of prior controlled trials including typical 
patient groups in clinical practice and reflecting current 
treatment approaches and include patients not enrolled into 
prior   trials because of high age, substantial cardiovascular 
risks, or concomitant medication.4
Within this context we considered it to be of considerable 
interest to compare the results on the effectiveness of office 
blood pressure measurement (OBPM) with data obtained dur-
ing ambulatory blood pressure measurement (ABPM). This is 
of relevance because several studies have demonstrated that 
BP reduction achieved in non interventional studies is higher 
than that observed in randomized clinical trials. Further, ABP 
is more closely related to cardiovascular morbidity and target 
organ damage and may therefore have a greater prognostic 
value.5,6 In patients with uncontrolled hypertension, Salles et al7 
showed that OBPM had no prognostic value, whereas ABPM 
correlated to cardiovascular morbidity and mortality.
Patients and methods
CHILI CU Soon was a prospective, noninterventional, 
noncontrolled, open-label, multi center study with a follow-up 
of at least 10 weeks. It was conducted by 1111 primary care 
physicians, internists, cardiologists, or diabetologists through-
out Germany. The study was registered at the Bundesinstitut 
für Arzneimittel und Medizinprodukte (BfArM) and the 
  Kassenärztliche Bundesvereinigung (KBV) in accordance 
with section 67(6) of the medicinal law. Applicable data pro-
tection Acts were respected. Participating physicians received 
remuneration for the documentation of patients, which was 
in accordance with the Gebührenordnung für Ärzte (GOÄ). 
Ethical approval was obtained prior to commencement of 
the study by the Freiburg Ethics Commission International, 
Germany, on March 23, 2009. Written informed consent was 
obtained from all patients.
Patients
High-risk patients aged at least 18 years were eligible for 
inclusion when a treatment decision had been made to start 
candesartan 32 mg plus HCTZ 12.5 mg or candesartan 32 mg 
plus HCTZ 25 mg due to arterial hypertension. Further 
inclusion criteria were uncontrolled BP ($140/90 mmHg 
or $130/80 mmHg in patients with metabolic syndrome 
or diabetes), on prior antihypertensive therapy for at least 
8 weeks, the presence of additional cardiovascular risk fac-
tors (eg, diabetes, dyslipidemia), and compliance with the 
prescribing information of Blopress® 32 mg PLUS 12.5 mg or 
Blopress 32 mg forte PLUS 25 mg (Takeda Pharma GmbH, 
Aachen, Germany). In case of an insufficient BP control at 
the first follow-up visit (at least 6 weeks after inclusion), 
physicians were allowed to increase the dose of HCTZ to 
25 mg (Blopress 32 mg forte PLUS 25 mg). Any concomitant 
medication was allowed as necessary.
Objectives
The primary objective was to document a change in BP with 
the introduction of candesartan cilexetil 32 mg and HCTZ 
12.5/25 mg. Secondary objectives were (1) to document 
the proportion of patients who reach the target BP or are 
  responders (DBP , 90 or reduction by $10 mmHg) using 
OBPM, (2) to determine the change in BP stratified accord-
ing to prior/concomitant therapies, and (3) to collect data on 
tolerability and drug safety in routine clinical practice.
Variables
Three visits were scheduled throughout a 10-week follow-up. 
At the first visit (enrollment), patient data, medical history, 
BP values, laboratory values, and previous and concomitant 
pharmacotherapy were documented. At the first follow-up 
visit (after 5–8 weeks), BP, concomitant pharmaco-
therapy, safety, and tolerability were assessed. At the last 
visit (.10 weeks after inclusion and at least 4 weeks after 
the first interim visit), BP, weight, body mass index, waist 
circumference, laboratory tests, prior and concomitant phar-
macotherapy, and safety/tolerability were documented.
Definitions
Normal OBP was ,140/90 mmHg for nondiabetic 
patients and ,130/80 mmHg for diabetic patients or those 
with metabolic syndrome. Diastolic responders were 
defined at a DBP ,90 mmHg or a reduction of at least 
10 mmHg vs baseline. Systolic responders were defined at 
a SDP ,140 mmHg or a reduction of at least 20 mmHg 
vs baseline.
Normal ABP values during the day were ,135/85 mmHg 
and ,120/70 mmHg during the night. Normal ABP values 
over 24 hours were ,130/80 mmHg. Normal dippers were Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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those with a reduction of $10% and ,20% of the daytime 
mean during the night. Nondippers were those with a reduc-
tion between $0% and ,10% of the daytime mean. Inverted 
dippers were those with a reduction of ,0% of the mean 
during daytime or an increase at night. Extreme dipping 
was defined as a reduction at night that exceeded 20% of the 
values during the day.
statistics
The case report forms were collected by the clinical research 
organization Factum GmbH, Offenbach, Germany, entered 
into a validated application based on ColdFusion MX 6.1 
(Adobe Systems Incorporated, Seattle, WA), and saved on 
an SQL Server 2003 (Microsoft, Redmond, WA). Case report 
forms were checked for consistency and a subset of the forms 
verified with the source data (8%).
Regarding safety, the trial was adequately sized (n = 5000) 
in order to identify rare AEs, ie, those that may not have been 
detected in previous clinical studies (incidence 1:1000), with 
a probability of .95%.
The statistical analysis was performed descriptively and 
was interpreted in an explorative way. Comparisons were 
made for a number of variables and analyzed using descrip-
tive statistics. Differences were calculated in patients with 
values at baseline and follow-up (per protocol), for both the 
OBPM group and the ABPM group. The last documented 
visit was regarded to be the follow-up value in case only 
the interim visit was documented. Data were analyzed using 
IBM® SPSS® Statistics 18 (IBM Corporation, Somer, NY). 
The tests applied are indicated in the legends of the tables 
and figures.
Results
Between June 2009 and December 2009 a total of 4131 patients 
were included (safety population), of which 4130 were avail-
able for the analysis (efficacy population). The mean age of all 
patients was 63.0 ± 11.0 years and 52.8% were male (Table 1). 
Frequent comorbid disease conditions were diabetes (51.3%), 
coronary artery disease (43.5%), angina pectoris (26.2%), heart 
failure (25.1%), and prior stroke (23.5%).
Blood pressure reduction with OBPM
BP at baseline was 162.1 ± 14.8/94.7 ± 9.2 mmHg (Table 2), 
which meant that 31.3% had mild, 48.4% moderate, and 
18.8% severe hypertension. After about 10 weeks of cande-
sartan 32 mg/12.5 mg or 25 mg HCTZ treatment, mean BP 
had lowered to 131.7 ± 10.5/80.0 ± 6.6 mmHg (P , 0.0001 
for both comparisons). A total of 91.0% were diastolic and 
77.2% systolic responders, resulting in 31.2% normaliza-
tion of those without diabetes or metabolic syndrome 
(,140/90 mmHg) and 8.6% for those with diabetes or 
metabolic syndrome (,130/80 mmHg). BP reduction was 
as effective in the total as in subgroups of patients defined 
by prior or concomitant medication (Table 3).
comparison of OBPM and ABPM values
Physicians regarded ABPM to be necessary in 351 
patients (because of suspected noncontrol over 24 hours). 
Table 1 Baseline characteristics of the study population
Variables Patients with OBPM ABPM and OBPM
No. available % No. available %
Males (%) 4130 52.8 351 57.5
Age (years ± sD) 4128 63.0 ± 11.0 351 62.1 ± 10.0
Body mass index (kg/m² ± sD) 4098 29.6 ± 5.3 350 30.3 ± 7.1
Waist circumference (cm ± sD) 3253 103.6 ± 14.2 318 104.5 ± 13.1
smokers (%) 4102 20.3 351 25.9
Comorbid disease conditions
Diabetes (%) 3601 51.3 241 53.5
coronary artery disease (%) 3669 48.9 248 60.9
Angina pectoris (%) 3418 26.2 239 40.2
Heart failure (%) 3443 25.1 244 34.8
stroke/TiA (%) 3322 23.5 232 33.1
Myocardial infarction (%) 3462 22.5 236 27.5
Peripheral arterial disease (%) 3371 15.4 232 20.3
Renal insufficiency (%) 3348 13.1 231 19.0
neuropathy (%) 3322 10.5 233 16.3
Retinopathy (%) 3324 9.8 231 19.9
Atrial fibrillation (%) 3352 9.8 233 16.7
Abbreviations: ABPM, ambulatory blood pressure measurement; OBPM, office blood pressure measurement; SD, standard deviation; TIA, transient ischemic attack.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Table 2 Blood pressure values at baseline and follow-up
Variables All patients with OBPM
Baseline Last visit  
(LOCF)
P-value
OBPM
sBP (mmHg) 162.1 ± 14.8 131.7 ± 10.5 ,0.0001
DBP (mmHg)   94.7 ± 9.2   80.0 ± 6.6 ,0.0001
Severity of hypertension (%) ,0.0001
,140 mmHg and  
,90 mmHg (%)a
1.5 74.0
140–159 mmHg or  
90–99 mmHg (%)
31.3 23.0
160–179 mmHg or  
100–109 mmHg (%)
48.4 2.7
$180 mmHg or  
$110 mmHg (%)
18.8 0.3
Normalization/response (%)
,130 mmHg and  
,80 mmHg (%)b
0.2 27.0 ,0.0001
,140 mmHg and  
,90 mmHg (%)c
2.5 37.0 ,0.0001
DBP ,90 mmHg or  
∆ $ 10 mmHg (%)
91.0
sBP , 140 mmHg or  
∆ $ 20 mmHg (%)
77.2
Notes:  aFor all patients;  bfor patients with diabetes or metabolic syndrome;  cfor 
patients without diabetes or metabolic syndrome. 
Abbreviations:  DBP,  diastolic  blood  pressure;  LOcF,  last  observation  carried 
forward; OBPM, office blood pressure measurement; SBP, systolic blood pressure.
Table 3 change in blood pressure (OBPM, n = 4130) stratified according to prior visit/concomitant therapies
SBP DBP
∆SBP P-value vs baseline ∆DBP P-value vs baseline
Prior but discontinued therapies
Ace inhibitors -30.7 ± 14.8 ,0.0001 -15.4 ± 9.6 ,0.0001
Angiotensin receptor blockers -27.9 ± 14.8 ,0.0001 -13.2 ± 9.7 ,0.0001
Beta blockers -31.3 ± 16.3 ,0.0001 -15.5 ± 10.3 ,0.0001
ccBs -31.2 ± 15.7 ,0.0001 -15.1 ± 10.5 ,0.0001
Diuretics -30.6 ± 16.1 ,0.0001 -15.2 ± 10.0 ,0.0001
none -30.1 ± 17.5 ,0.0001 -16.3 ± 11.8 ,0.0001
Prior and continued therapies
Ace inhibitors -30.4 ± 15.4 ,0.0001 -14.3 ± 8.9 ,0.0001
Angiotensin receptor blockers -25.3 ± 25.8 ,0.0001  - 9.0 ± 14.8 ,0.0001
Beta blockers -30.2 ± 16.2 ,0.0001 -14.3 ± 10.6 ,0.0001
ccBs -30.6 ± 16.4 ,0.0001 -14.2 ± 10.6 ,0.0001
Diuretics -29.9 ± 16.9 ,0.0001 -13.3 ± 11.2 ,0.0001
Abbreviations:  ACE,  angiotensin-converting  enzyme;  CCB,  calcium  channel  blocker;  DBP,  diastolic  blood  pressure;  OBPM,  office  blood  pressure  measurement; 
sBP, systolic blood pressure.
These patients were more likely to be male (57.5% vs 52.8%) 
and smokers (25.9% vs 20.3%) and had a considerably higher 
burden of comorbid disease conditions such as coronary 
artery disease (60.9% vs 48.9%), angina pectoris (40.2% 
vs 26.2%), heart failure (34.8% vs 25.1%), and retinopathy 
(16.7% vs 9.8%) (Table 1).
In these patients, BP at baseline was 158.2 ± 14.4/ 
93.7 ± 10.0 mmHg during the day and 141.8 ± 16.9/85.2 ± 
10.5 mmHg during the night (Table 4). At the last visit, BP 
was   significantly reduced to 133.6 ± 10.0/80.0 ± 6.6 mmHg 
and 121.0 ± 12.2/72.3 ± 7.4 mmHg, respectively, resulting in 
20.8% being normotensive over 24 hours (,130/80 mmHg).
The correlation between OBPM and ABPM was good 
with r = 0.589 for SBP (Figure 1) and r = 0.389 for DBP 
during the day (Figure 2).
Of  those  who  were  normotensive  upon  OBPM 
(,140/90 mmHg), 35.1% had high ABPM during the day, 
49.8% were nondippers, and 3.4% were inverted dippers 
(Table 5). Of those who were hypertensive during their office 
visit, 21.1% had a normal BP during ABPM at daytime and 
7.1% at nighttime. Again, there was a larger subset whose 
BP pattern was compatible with a nondipping or inverted 
dipping pattern.
number of patients with (serious)  
adverse events
The mean serum potassium value was 4.41 ± 0.55 at baseline 
and 4.36 ± 0.63 at follow-up. This was a statistically signifi-
cant reduction of the mean serum potassium (P = 0.013). This 
was reflected in 10.6% with hyperkalemia at baseline and 
only 7.8% during follow-up. Reductions were also signifi-
cant in the subgroup of patients with only candesartan as a 
renin-angiotensin system blocker but not in those receiving 
two different renin-angiotensin system blocking agents. 
A direct comparison, however, yielded no significant results 
(P = 0.476). During the course of the observation, 49 AEs 
were reported in patients receiving a fixed combination of Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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Table 4 Blood pressure values at baseline and follow-up
Variables Patients with ABPM
Baseline Last visit (LOCF) P-value
ABPM day
systolic blood pressure (mmHg) 158.2 ± 14.4 133.6 ± 10.6 ,0.0001
Diastolic blood pressure (mmHg) 93.7 ± 10.0 80.0 ± 6.6 ,0.0001
ABPM night
systolic blood pressure (mmHg) 141.8 ± 16.9 121.0 ± 12.2 ,0.0001
Diastolic blood pressure (mmHg) 85.2 ± 10.5 72.3 ± 7.4 ,0.0001
ABPM 24 hours mean
systolic blood pressure (mmHg) 151.7 ± 13.7 128.9 ± 10.2 ,0.0001
Diastolic blood pressure (mmHg) 90.4 ± 9.0 77.5 ± 6.4 ,0.0001
severity of hypertension ,0.0001
,135 mmHg and ,85 mmHg (%) 0.9 53.0
135–146 mmHg or 85–89 mmHg (%) 6.0 33.6
147–156 mmHg or 90–95 mmHg (%) 29.3 10.3
$157 mmHg or $96 mmHg (%) 63.8 3.1
Abbreviations: ABPM, ambulatory blood pressure measurement; LOcF, last observation carried forward.
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Figure 1 systolic OPBM vs ABPM during the day. 
Abbreviations: ABPM, ambulatory blood pressure measurement; OBPM, office blood pressure measurement.
32 mg candesartan with either 12.5 mg HCTZ or 25 mg 
HCTZ (n = 49/4131; 1.19%). Of these, seven (0.17%) were 
regarded as serious. Most AEs were related to the ner-
vous system (n = 13; 0.31%) or cardiac disorders (n = 12; 
n = 0.29%). Details are displayed in Table 6   (MedDRA® 
Primary System Organ Classes, Northrop Grummon 
  Corporation, California, US).
Discussion
CHILI CU Soon demonstrated that 32 mg candesartan in 
combination with 12.5 mg HCTZ or 25 mg HCTZ is safe 
and effective at lowering BP in patients who are uncontrolled 
on prior antihypertensive therapy. Patients were at high 
cardiovascular risk, as exemplified by the high prevalence 
of diabetes, angina pectoris/coronary artery disease, and Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
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Figure 2 Diastolic OPBM vs ABPM during the day. 
Abbreviations: ABPM, ambulatory blood pressure measurement; OBPM, office blood pressure measurement.
Table 5 comparison of OBPM and ABPM blood pressure values
OBPM
,140/90 mmHg $140 mmHg or $90 mmHg Total
n % n % n %
ABPM day
normal (,135/85 mmHg) 190 64.9 27 21.1 225 52.0
High ($135 or $85 mmHg) 107 35.1 101 78.9 208 48.0
Total 305 100.0 128 100.0 433 100.0
ABPM 24 hours
normal (,130/80 mmHg) 79 26.7 9 7.1 88 20.8
High ($130 mmHg or $80 mmHg) 217 73.3 118 92.9 335 79.2
Total 296 100.0 127 100.0 423 100.0
ABPM dipping
normal dippera 119 40.3 48 38.7 167 39.9
nondipperb 147 49.8 64 51.6 211 50.4
inverted dipperc 10 3.4 7 5.7 17 4.1
extreme dipperd 19 6.4 5 4.0 24 5.7
Total 295 100.0 124 100.0 419 100.0
Notes: anormal dipper (reduction $10% and ,20% of the daytime mean); bnondipper (reduction between $0% and ,10% of the daytime mean); cinverted dipper (reduction 
of ,0% of the mean during daytime or an increase at night); dextreme dipper (reduction at night that exceeded 20% of the values during the day). 
Abbreviations: ABPM, ambulatory blood pressure measurement; OBPM, office blood pressure measurement.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Table 6 number of patients with Aes or sAes during survey 
and Aes coded by MedDRA® Version 11.1 (safety population, 
n = 4131)
Type of adverse event n %
no Ae 4082 98.81
Any Ae 49 1.19
serious Ae 7 0.17
not serious 42 1.02
MedDRA® Primary System Organ Class AEs
nervous system disorders 13 0.31
cardiac disorders 12 0.29
investigations 5 0.12
skin and subcutaneous tissue disorders 4 0.10
general disorders and administration site  
conditions
3 0.07
Vascular disorders 3 0.07
Musculoskeletal and connective tissue disorders 3 0.07
gastrointestinal disorders 2 0.05
Renal and urinary disorders 2 0.05
MedDRA® Primary System Organ Class SAEs
nervous system disorders 3 0.07
Vascular disorders 1 0.02
Renal and urinary disorders 1 0.02
Metabolism and nutrition disorders 1 0.02
cardiac disorders 1 0.02
Abbreviations: Ae, adverse event; sAe, serious adverse event.
heart failure. After about 10 weeks of treatment, mean BP 
had lowered by 30.4/14.7 mmHg from a baseline value of 
162.1 ± 14.8/94.7 ± 9.2 mmHg. In a patient subgroup at risk, 
ABPM was performed and indicated that about 40% had a 
normal dipping pattern, whereas about 60% were nondippers 
or even inverted dippers.
effectiveness in clinical practice in the 
context of recent controlled trials
The extent of BP reduction with candesartan/HCTZ 
depends on BP at baseline and the dose used. A variety 
of combinations with different doses of up to 32 mg 
candesartan and up to 25 mg HCTZ has been tested and 
found to be effective in clinical trials.1,2,8,9 Uen et al,1 for 
example, demonstrated that replacing previously ineffec-
tive antihypertensive drugs with candesartan/HCTZ in 
patients with uncontrolled arterial hypertension signifi-
cantly reduced BP and markers of ischemic stress such 
as ST-segment depression. In respect of the doses used in 
the present study, Edes2 observed mean reductions in SBP 
and DBP that were significantly greater with candesartan 
32 mg/HCTZ 25 mg (21/14 mmHg) than with candesartan 
32 mg (13/9 mmHg) or HCTZ 25 mg alone (12/8 mmHg) 
or placebo (4/3 mmHg) (P , 0.001 for all comparisons). 
The proportion of patients with controlled BP (SBP , 
140 mmHg and DBP , 90 mmHg) at the end of this 
study was also significantly greater in the candesartan 
32 mg/HCTZ 25 mg group (63%) than in the other treat-
ment groups (P , 0.001 for all comparisons). Bönner3 
investigated the efficacy of candesartan 32 mg in combina-
tion with HCTZ 12.5 mg or 25 mg in patients who were 
not optimally controlled using candesartan monotherapy. 
Mean BP (153/97 mmHg at baseline) was further reduced 
by 13.0/8.8 mmHg in the fixed combination with the 
HCTZ 12.5 mg group and by 15.5/10.0 mmHg in the fixed 
combination with HCTZ 25 mg group (P , 0.01 for all 
between-treatment comparisons). Against this background 
the results of the present noninterventional trial deserve to 
be noted, with a mean BP reduction of 30.4/14.7 mmHg. BP 
reduction was consistent and similar across all subgroups 
of patients defined by prior but discontinued therapies, con-
comitant therapies, and cardiovascular risk at baseline.
comparison of OBPM and ABPM
BP readings obtained by OBPM and ABPM were quite 
similar at baseline (162.1 ± 14.8/94.7 ± 9.2 mmHg vs 
158.2 ± 14.4/93.7 ± 10.0 mmHg) and at follow-up (131.7 ± 
10.5/80.0 ± 6.6 mmHg vs 133.6 ± 10.6/80.0 ± 6.6 mmHg). 
There was also a high degree of correlation between OBPM 
and ABPM (r = 0.589 for SBP and r = 0.389 for DBP) during 
the day in our study, which mirrors previous analyses that 
reported correlations coefficients of 0.41 for DBP (Mengden 
et al)10 and 0.73 for DBP and 0.64 for SBP (Head et al).11 
Although the study by Mengden et al10 was a randomized 
controlled trial, the study by Head et al11 was a prospective 
cohort study that was biased toward those being referred for 
ambulatory assessment.
A high proportion of at-risk patients had normal BP 
  readings during OBPM but a nondipping or even inverted 
dipping BP pattern at night. This may have been because of 
the noninterventional study type in which patients were sched-
uled only for ABPM when it was considered to be reasonable 
by the treating physician. In fact, about 60% of patients were 
documented to have either nondipping or inverted dipping 
of BP, suggesting that a tailored intervention (eg, bedtime 
medication) would be beneficial in those patients. On the 
other hand, the results clearly illustrate that achieving a 
normal BP during OBPM does not necessarily mean satis-
factory BP control over 24 hours, reinforcing previous calls 
for a more comprehensive work-up of hypertensive patients, 
including ABPM.12Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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safety and tolerability
Candesartan/HCTZ is generally well tolerated in patients 
with mild to moderate hypertension. Combined data from 
five randomized, double-blind, placebo-controlled clinical 
trials indicated that AEs during candesartan/HCTZ therapy 
are uncommon and that few were serious.13 The AE profile 
of candesartan 32 mg in combination with 12.5 mg or 25 mg 
HCTZ, in particular, is likewise safe.2,3 Bönner3 reported 
about 1% serious AEs when candesartan combination therapy 
including HCTZ was considered. For metabolic parameters, 
a slight increase of serum ureate and serum creatinine 
was observed with the fixed combinations, whereas other 
  parameters were essentially unchanged. Edes2 reported a rate 
of serious AE for the fixed-dose combination that was even 
lower compared with placebo (0.2% vs 3.1%), with overall 
AE rate ranging between 23% and 25% for placebo, HCTZ, 
candesartan, and their combination. The present trial reas-
sures that the high-dose fixed combination of candesartan 
and HCTZ is well tolerated, with 1.2% of patients having 
AEs and 0.2% having serious AEs, a proportion that is lower 
than the rates previously reported from randomized trials but 
about comparable with recent data from primary care.14 This 
is also consistent with findings that reported systematically 
lower AE rates in noninterventional studies than in random-
ized controlled trials, because of the lessened observation 
and reporting.
Limitations
Observational studies in primary care, including typical 
patient groups and reflecting current treatment approaches, 
are useful for complementing the findings of randomized 
controlled trials.4 The present results have to be considered 
against the background of potential limitations, however. 
First, the study was not controlled and therefore the role 
of a placebo effect or the withdrawal of antihypertensive 
agents is unknown. Second, in the absence of a randomiza-
tion procedure, the influence of unknown biases, eg, through 
patient selection, cannot be ruled out. Third, because of the 
concurrent documentation of a 12.5 mg and 25 mg HCTZ 
combination with 32 mg candesartan and their addition to, 
or substitution for, other medications, bias cannot be ruled 
out. Fourth, because ABPM was not mandatory, the number 
of patients with both OBPM and ABPM is limited to about 
25% of all patients. Because ABPM is usually performed in 
clinical practice in patients whose BP is difficult to control, 
ABPM may not be completely representative for the total 
OBPM population.12 This may explain the high proportion 
of nondipping patients.
Conclusion
Candesartan 32 mg in a fixed-dose combination with either 
12.5 mg or 25 mg HCTZ is safe and effective for BP lowering 
in patients at high cardiovascular risk, irrespective of prior 
antihypertensive drug class not being able to control BP.
Acknowledgments
This noninterventional study was conducted by Takeda 
Pharma GmbH, Aachen, Germany. We would like to thank 
the participating physicians for their assistance and all patients 
observed during the study. Special gratitude goes to the clini-
cal research organization Factum GmbH for data processing 
and conducting the statistical analyses. Takeda Pharma GmbH 
(Reinhold Hübner) designed the study. Thomas Mengden and 
Peter Bramlage explored the data and requested statistical 
analyses from the Factum GmbH (responsible statistician 
Dr Michael Vornkahl). Peter   Bramlage wrote the first draft 
of the manuscript. Thomas Mengden and Reinhold Hübner 
revised the manuscript for important intellectual content. All 
authors reviewed and approved the final manuscript.
Disclosure
Thomas Mengden and Peter Bramlage have received research 
support and honoraria for medical consulting. Reinhold   Hübner 
is an employee of the sponsor, Takeda Pharma GmbH.
References
1.  Uen S, Un I, Fimmers R, Vetter H, Mengden T. Effect of candesartan 
cilexetil with hydrochlorothiazide on blood pressure and ST-segment 
depression in patients with arterial hypertension. Dtsch Med   Wochenschr. 
2007;132(3):81–86.
2.  Edes I. Combination therapy with candesartan cilexetil 32 mg and 
hydrochlorothiazide 25 mg provides the full additive antihypertensive 
effect of the components: a randomized, double-blind, parallel-group 
study in primary care. Clin Drug Investig. 2009;29(5):293–304.
3.  Bönner G. Antihypertensive efficacy and tolerability of candesartan-
hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not opti-
mally controlled with candesartan monotherapy. Blood Press. 2008; 
17(Suppl 2):22–30.
4.  Concato J, Shah N, Horwitz RI. Randomized, controlled trials, obser-
vational studies, and the hierarchy of research designs. N Engl J Med. 
2000;342(25):1887–1892.
5.  Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic 
blood pressure measurement in predicting mortality: the Dublin outcome 
study. Hypertension. 2005;46(1):156–161.
6.  Clement DL, De Buyzere ML, De Bacquer DA, et al. Prognostic 
value of ambulatory blood-pressure recordings in patients with treated 
  hypertension. N Engl J Med. 2003;348(24):2407–2415.
7.  Salles GF, Cardoso CR, Muxfeldt ES. Prognostic influence of office and 
ambulatory blood pressures in resistant hypertension. Arch Intern Med. 
November 24, 2008;168(21):2340–2346.
8.  Bramlage P, Schonrock E, Odoj P, Wolf WP, Funken C. Importance of 
a fixed combination of AT1-receptor blockade and hydrochlorothiazide 
for blood pressure lowering in cardiac risk patients. A postmarketing 
surveillance study with Candesartan/HCTZ. MMW Fortschr Med. 
2008;149(Suppl 4):172–181.Vascular Health and Risk Management
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/vascular-health-and-risk-management-journal
Vascular Health and Risk Management is an international, peer-
reviewed journal of therapeutics and risk management, focusing on 
concise rapid reporting of clinical studies on the processes involved 
in the maintenance of vascular health; the monitoring, prevention and 
treatment of vascular disease and its sequelae; and the involvement of 
metabolic disorders, particularly diabetes. This journal is indexed on 
PubMed Central and MedLine. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
769
cHiLi cU soon
  9.  Azizi M, Nisse-Durgeat S, French Collaborative Group. Comparison 
of the antihypertensive effects of the candesartan 8 mg hydrochlorothi-
azide 12.5 mg combination vs the valsartan 80 mg hydrochlorothiazide 
12.5 mg combination in patients with essential hypertension resistant 
to monotherapy [abstract no. P2.367]. J Hypertens. 2004;22(Suppl 2): 
S254–S255.
  10.  Mengden T, Binswanger B, Weisser B, Vetter W. An evaluation of self-
measured blood pressure in a study with a calcium-channel antagonist 
versus a beta-blocker. Am J Hypertens. 1992;5(3):154–160.
  11.  Head GA, Mihailidou AS, Duggan KA, et al. Definition of ambulatory 
blood pressure targets for diagnosis and treatment of hypertension 
in relation to clinic blood pressure: prospective cohort study. BMJ. 
2010;340:c1104.
  12.  Luders S, Franz IW, Hilgers KF, et al. Twenty-four hour ambulatory 
blood pressure monitoring. Dtsch Med Wochenschr. 2005;130(46): 
2664–2668.
  13.  Belcher G, Hubner R, George M, Elmfeldt D, Lunde H. Candesartan 
cilexetil: safety and tolerability in healthy volunteers and patients with 
hypertension. J Hum Hypertens. Sep 1997;11(Suppl 2):S85–S89.
  14.  Bönner G, Landers B, Bramlage P. Candesartan cilexitil/hydrochloro-
thiazide combination treatment versus high-dose candesartan cilexetil 
monotherapy in patients with mild to moderate cardiovascular risk 
(CHILI Triple T). Vasc Health Risk Manag. 2011;7:85–95.